Insitro Platform
Machine Learning to Unravel Biology and Redefine Disease for Better Drugs, Faster.
Executive Summary
Insitro Platform is an AI/ML-driven research and development platform that integrates high-throughput in vitro cellular data with human clinical data. It is used by pharmaceutical companies and drug hunters to build predictive models, identify novel drug targets, and accelerate the discovery and development of new medicines. The platform's key value lies in its ability to de-risk and accelerate multiple steps in the R&D value chain, aiming to bring better drugs to patients faster.
Use Cases
- Identifying novel genetic targets for various diseases.
- Accelerating the discovery and development of new medicines.
- Designing and optimizing small molecules, antibodies, and oligonucleotides.
- Developing treatments for metabolic diseases, such as NASH and fatty liver diseases.
- Discovering therapies for neurodegenerative diseases like ALS and frontotemporal dementia.
- Optimizing clinical trial design by predicting patient response and identifying appropriate endpoints.
Features
Visibility
- Disease Phenotype Identification: Ability to identify subtle disease-related phenotypes in cells that are not discernible to the human eye, using machine learning models.
- Novel Target Uncovering: Rapidly uncovers novel genetic targets and therapeutic hypotheses by leveraging human and cellular data.
- Biomarker and Imaging Analysis: Advanced analysis of medical imaging and circulating biomarkers from large patient cohorts to identify disease associations.
Intelligence
- Predictive Disease Modeling: Builds predictive models of human diseases to understand their underlying biology and accelerate drug development.
- AI-Driven Molecular Design: Designs small molecules, antibodies, oligonucleotides, and other complex biologics with optimized properties using AI.
- Causal Intervention Point Identification: Leverages human genetics to identify causal intervention points in disease for effective therapeutic interventions.
- Accelerated Drug Development: Optimizes the drug discovery process, speeding up the identification of lead candidates and reducing time to market.
Support
- Collaborative R&D Partnerships: Engages in strategic collaborations with pharmaceutical companies, providing expertise and platform access for joint drug discovery programs.
- Scientific Publications & Presentations: Regularly publishes research and presents findings at scientific conferences, contributing to the broader scientific community.
Technical Specifications
- Architecture
- ML-driven platform integrating in vitro cellular data and human clinical data with a unified data architecture storage.
- Deployment
- Cloud/SaaS
- Authentication
- N/A
- API Available
- Yes
- MCP Server
- No
AI/ML Stack
- Machine Learning
- Generative AI
- Convolutional Neural Networks
Integrations
- Automated Labs
- Genomics Data
- Clinical Records
Security & Compliance
Encryption: N/A
Pricing
- Model
- Partnership-based, including upfront payments, milestone payments, and potential royalties.
- Starting Price
- Contact sales
- Target Customer
- Major pharmaceutical companies, Biopharma enterprises
- Contract Type
- Long-term strategic partnerships, multi-year agreements
- Free Trial
- No (credit card required)
About Insitro
Insitro is a machine learning-enabled drug discovery and development company that integrates multimodal data from human cohorts and cellular models with the power of AI and machine learning. The company aims to uncover genetic targets and new therapeutic hypotheses to accelerate the discovery and development of novel medicines.